Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$72.24 USD

72.24
3,456,659

-1.43 (-1.94%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $72.03 -0.21 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

by Zacks Equity Research

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Boston Scientific (BSX) Closes the Relievant Medsystems Buyout

by Zacks Equity Research

Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.

DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

National Vision's (EYE) Market Expansion Aids, Inflation Ails

by Zacks Equity Research

National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.

Myriad Genetics (MYGN) Expands Pharma Services With New Pact

by Zacks Equity Research

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost

by Zacks Equity Research

Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.

Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics

by Zacks Equity Research

Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.

Zacks.com featured highlights include DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services

by Zacks Equity Research

DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services are part of the Zacks Screen of the Week article.

Nemaura (NMRD) to Expand in UK With Metabolic Health Program

by Zacks Equity Research

The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.

Neogen's (NEOG) Innovation Aids, Currency Headwind Stays

by Zacks Equity Research

Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.

Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Charles River (CRL) Widens CliniPrime GMP Suite With New Launch

by Zacks Equity Research

Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.

Tirthankar Chakraborty headshot

4 Best Stocks Exhibiting Solid Earnings Growth

by Tirthankar Chakraborty

Invest in stocks such as DexCom (DXCM), Arthur J. Gallagher (AJG), Limbach (LMB) and Hartford Financial Services (HIG) for superb earnings growth.

Paragon 28 (FNA) New Staple System Expands Ankle Device Line

by Zacks Equity Research

Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.

Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes

by Zacks Equity Research

Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

by Zacks Equity Research

QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.

Illumina (ILMN) Launches Initiative on Pathogen Sequencing

by Zacks Equity Research

Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.

Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth

by Zacks Equity Research

Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

by Zacks Equity Research

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

by Zacks Equity Research

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.